Enwave Corporation Stock
?
Your prediction
Enwave Corporation Stock
Pros and Cons of Enwave Corporation in the next few years
Pros
Cons
Performance of Enwave Corporation vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enwave Corporation | 3.230% | -8.284% | -10.920% | 0.649% | -34.322% | -50.949% | -83.475% |
| Aurinia Pharmaceuticals Inc. | 0.400% | 0.850% | 7.020% | 109.279% | 1.299% | 48.800% | 26.930% |
| Spectral Medical Inc | 1.200% | -4.023% | 1.829% | 85.556% | 5.031% | 313.366% | 137.216% |
| Xenon Pharmaceuticals Inc. | 1.210% | 1.215% | -2.913% | 72.414% | 31.579% | 47.929% | - |
News
EnWave Reports 2026 First Quarter Consolidated Interim Financial Results
Vancouver, B.C., February 20th, 2026. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the first
EnWave Signs Royalty-Bearing License with Bowen Gumlu Grower’s Association of Australia
Vancouver, B.C., February 2nd, 2026, EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today announced that the Company has signed a royalty-bearing commercial license
EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results
Vancouver, B.C., December 15th, 2025 / EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the fourth

